Aria Pharmaceuticals Inc. has synthesized compounds acting as caspase-1 (IL-1β-converting enzyme) and pyroptosis inhibitors reported to be useful for the treatment of alopecia, autoimmune hemolytic anemia, chronic kidney disease, duodenal ulcer, hepatitis B, osteoarthritis, systemic lupus erythematosus and uveitis, among others.

Aria Pharmaceuticals Inc. has described C-C chemokine receptor type 2 (CCR2; MCP-1-R) modulators reported to be useful for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.